Acinetobacter infectious disease

This study is checking how safe the antibiotic sulbactam-durlobactam is for people hospitalized with a hard-to-treat bacterial infection called Acinetobacter baumannii. Researchers will watch 100 participants for about 28 days to see if they have any side effects, especially alle…

This study tests a combination of two antibiotics, aztreonam and avibactam, in newborns and infants up to 9 months old who have serious infections caused by gram-negative bacteria. The trial has two parts: one to see how a single dose moves through the body, and another to test m…

This study is testing an antibiotic called Sulbactam-Durlobactam in hospitalized children from birth to under 18 years old who have or may have an Acinetobacter infection. The goal is to find the right dose and check that it is safe. About 48 children will receive the drug throug…

This study tests three different antibiotic combinations to treat a dangerous, drug-resistant bacteria called CRAB that causes infections in intensive care patients. Researchers will compare colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline in 108 su…

This study tests whether adding a second antibiotic (fosfomycin) to the standard antibiotic (ceftazidime) helps people with severe gram-negative infections recover faster. About 100 hospitalized adults will be randomly assigned to get either the combo or the standard drug plus a …

This study observes 600 patients in Korea who receive Zavicefta for complicated abdominal or urinary tract infections or hospital-acquired pneumonia. Researchers track side effects and how well the drug works. It is required by Korean regulators to ensure the drug's safety after …

This study is observing 200 hospitalized adults with carbapenem-resistant Acinetobacter baumannii (CRAB) infections—a type of superbug—who are treated with the antibiotic sulbactam-durlobactam. Researchers will compare their outcomes to patients receiving other treatments to see …